This Article Full Text Full Text (PDF) Perspective on this Article All Versions of this Article: 1940-6207.CAPR-08-0232v1 2/11/942    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Google Scholar Articles by Murillo, G. Articles by Mehta, R. G. PubMed PubMed Citation Articles by Murillo, G. Articles by Mehta, R. G. Related Collections Preclinical Intervention Preclinical Intervention: In Vitro: Drugs, Mechanisms Commentary

Deguelin Inhibits Growth of Breast Cancer Cells by Modulating the Expression of Key Members of the Wnt Signaling Pathway

Authors' Affiliations: ¹ Division of Carcinogenesis and Chemoprevention, IIT Research Institute, Chicago, Illinois, and ² GenUs BioSystems, Northbrook, Illinois

Requests for reprints: Rajendra G. Mehta, IIT Research Institute, 10 West 35th Street, Chicago, IL 60616. Phone: 312-567-4970; Fax: 312-567-4931; E-mail: rmehta{at}iitri.org.

An emphasis in early detection and more effective treatments has decreased the mortality rate of breast cancer. Despite this decrease, breast cancer continues to be the leading cause of death among women between 40 and 55 years of age and is the second overall cause of death among women. Hence, the aim of the present study was to assess the therapeutic efficacy of deguelin, a rotenoid isolated from several plant species, which has been reported to have chemopreventive and/or chemotherapeutic effects in skin, mammary, colon, and lung cancers. The effect of deguelin on cell proliferation was evaluated using four human breast carcinoma cell lines (MCF-7, BT474, T47D, and MDA-MB-231) by cell count and MTT. Moreover, apoptosis was evaluated by acridine/ethidium staining and DNA laddering. Gene expression changes following deguelin treatment in MDA-MB-231 cells was assessed through microarray analysis. Deguelin at 1 µmol/L was found to inhibit the growth of the breast cancer cell lines tested with a range of 37% to 87%. The highest inhibition was noted for the MDA-MB-231 cell line (MDA-MB-231>BT474>MCF7>T47D>MCF12F). An arrest at the S phase of the cell cycle and apoptosis were shown in the MDA-MB-231 cells treated with deguelin. The microarray profile indicated differential expression of two independent pathways, including clusters of apoptosis and Wnt/β-catenin signaling genes in cells as a result of deguelin treatment. These studies support the antiproliferative effects of deguelin in human breast cancer cells and, perhaps more importantly, illustrate novel actions by deguelin in the Wnt signaling pathway.

Key Words: Deguelin • MDA-MB-231 cells • Wnt Signaling • Apoptosis • Breast Cancer

Commentary

A Novel Look into Estrogen Receptor–Negative Breast Cancer Prevention with the Natural, Multifunctional Signal Transduction Inhibitor Deguelin

Jennifer M. Rodenberg and Powel H. Brown
Cancer Prevention Research 2009 2: 915-918. [Abstract] [Full Text] [PDF]

This article has been cited by other articles:

				J. M. Rodenberg and P. H. Brown A Novel Look into Estrogen Receptor-Negative Breast Cancer Prevention with the Natural, Multifunctional Signal Transduction Inhibitor Deguelin Cancer Prevention Research, November 1, 2009; 2(11): 915 - 918. [Abstract] [Full Text] [PDF]